Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...2829303132333435363738...5960»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas. (Pubmed Central) -  Jul 14, 2021   
    CDKN2A inhibited the bio‑activity by modulating CDK4, and high CDKN2A predicted the insensitivity to CDK4 inhibitor, palbociclib, in somatotroph adenoma patients. In summary, the present study shows CDKN2A inhibited the bio‑activity by modulating CDK4, and high CDKN2A predicts the insensitivity to CDK4 inhibitor, Palbociclib, in somatotroph adenoma patients.
  • ||||||||||  Journal:  The Role of Growth Hormone in Depression: A Human Model. (Pubmed Central) -  Jul 13, 2021   
    The study also suggests that hormones should be factored into the matrix that entails the neuro-biological underpinnings of depressive disorders. Future work could explore the mechanisms involved, further brain and neuropeptide interactions, and, novel potential therapeutic targets in depressive and other mental health disorders.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  A Prospective Study of Outcome After Therapy for Acromegaly (clinicaltrials.gov) -  Jul 13, 2021   
    P=N/A,  N=250, Recruiting, 
    Future work could explore the mechanisms involved, further brain and neuropeptide interactions, and, novel potential therapeutic targets in depressive and other mental health disorders. Trial completion date: Jun 2020 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2022
  • ||||||||||  Trial completion date, Trial primary completion date:  Treatment Patterns and Treatment Outcomes for Acromegaly (clinicaltrials.gov) -  Jul 13, 2021   
    P=N/A,  N=520, Recruiting, 
    Trial completion date: Jun 2020 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2022 Trial completion date: Jul 2020 --> Jul 2023 | Trial primary completion date: Jul 2019 --> Jul 2022
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Trial completion, Enrollment change:  Bone MicroArchitecture in Acromegaly (clinicaltrials.gov) -  Jul 13, 2021   
    P=N/A,  N=77, Completed, 
    Trial completion date: Jul 2020 --> Jul 2023 | Trial primary completion date: Jul 2019 --> Jul 2022 Recruiting --> Completed | N=25 --> 77
  • ||||||||||  Retrospective data, Review, Journal:  Global epidemiology of acromegaly: a systematic review and meta-analysis. (Pubmed Central) -  Jul 11, 2021   
    Although the largest amount of heterogeneity was due to the high precision of the studies' estimates, data source and geographic area could represent relevant study-levels factors which could explain about 50% of the total between-study variability. Large-scale high quality studies on the epidemiology of acromegaly are warranted to help the public health system in making decisions.
  • ||||||||||  Clinical, Review, Journal:  Patient-centred outcomes with pituitary and parasellar disease. (Pubmed Central) -  Jul 10, 2021   
    In order to maintain in the long-term a good quality of life, patients need to adapt to this new situation, something that may be difficult, since they often cannot continue with all the activities and rhythm they used to do. Depression is often the consequence of maladaptation to the new situation, leading to impaired quality of life.
  • ||||||||||  cabergoline / Generic mfg.
    Clinical, Journal:  Unilateral hydrocephalus from a gangliocytoma-somatotrophinoma: first reported case. (Pubmed Central) -  Jul 9, 2021   
    Despite the residual disease, his vision recovered remarkably, low-dose cabergoline controlled residual excess growth hormone (GH) secretion, and the residual tumour has remained extremely stable over 2 years...Growth hormone (GH)-producing SGPAs are less likely to respond to somatostatin agonists than classic somatotrophinomas. Primary surgical debulking via a trans-sphenoidal approach was effective in this individual, leading to the restoration of CSF circulation and improvement in visual disturbance, while also negating the need for permanent CSF diversion despite the residual tumour burden.
  • ||||||||||  Journal:  Mechanisms of putative IGF-I receptor resistance in active acromegaly. (Pubmed Central) -  Jul 7, 2021   
    The development of a degree of IGF-IR resistance for metabolic actions may help to explain why in active acromegaly diabetogenic effects of GH predominate and are not completely counteracted and neutralized by elevated circulating levels of IGF-I. Further studies are necessary in order to support this hypothesis.
  • ||||||||||  Journal:  Hyperprolactinemia in Acromegaly is Related to Prolactin Secretion by Somatolactotroph Tumours. (Pubmed Central) -  Jul 7, 2021   
    The absence of a difference in tumour volume between patients with hyper- and normoprolactinemia suggests that the hyperprolactinemia is likely to be caused by the co-secretion of growth hormone and prolactin by the tumour. Finally, for the first time, the cut-off of 10% of prolactin cells was validated for the diagnosis of somatolactotroph tumours in acromegaly.
  • ||||||||||  Clinical, Journal:  Impact of obstructive sleep apnea on cardiovascular risk in patients with acromegaly. (Pubmed Central) -  Jul 7, 2021   
    Patients who have both of these poor prognostic factors should be aggressively treated with surgery, medication, and probably radiation to optimally control the disease. The coexistence of OSA might increase the CVD risk for patients with acromegaly, and IR might independently contribute to CVD risk in acromegalic patients with OSA.
  • ||||||||||  Acromegaly (Twitter) -  Jul 6, 2021   
  • ||||||||||  Review, Journal:  Hypothalamic-Pituitary Diseases and Erectile Dysfunction. (Pubmed Central) -  Jul 4, 2021   
    In addition, excess and deficiency of pituitary hormones or metabolic alterations that are associated with some pituitary diseases (e.g., Cushing's disease and acromegaly, hypopituitarism) can determine the development of ED with different mechanisms. Thus, the present review aimed to explore the relationship between hypothalamic and pituitary diseases based on the most recent clinical and experimental evidence.
  • ||||||||||  Journal:  Gastrointestinal and renal involvement in systemic vasculitis. (Pubmed Central) -  Jun 30, 2021   
    GI involvement limited to the duodenum in the setting of ANCA-MPO vasculitis is a rare condition. Moreover, histopathologic confirmation of vasculitis in endoscopic biopsy samples is exceptional.
  • ||||||||||  Journal:  Evaluation of hypophysectomy for treatment of hypersomatotropism in 25 cats. (Pubmed Central) -  Jun 30, 2021   
    Moreover, histopathologic confirmation of vasculitis in endoscopic biopsy samples is exceptional. This study shows the beneficial outcome of hypophysectomy in cats with hypersomatotropism, marked by low death rate and a high percentage of diabetic remission and definitive cure.
  • ||||||||||  Journal:  Discovery of substituted 3H-pyrido[2,3-d]pyrimidin-4-ones as potent, biased, and orally bioavailable sst2 agonist. (Pubmed Central) -  Jun 23, 2021   
    This class of molecules exhibits excellent sst2 potency and selectivity against sst1, sst3, and sst5 receptors, and they are significantly more potent at inhibiting cAMP production than inducing internalization. The orally bioavailable 6-(3-chloro-5-methylphenyl)-3-(3-fluoro-5-hydroxyphenyl)-5-({methyl[(2S)-pyrrolidin-2-ylmethyl]amino}methyl)-3H,4H-pyrido[2,3-d]pyrimidin-4-one (36) also suppresses GH secretion in GHRH-challenged rats in a dose-dependent manner.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
    Clinical, Journal:  GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1. (Pubmed Central) -  Jun 23, 2021   
    Lanreotide-Autogel 120 mg/month reduced GHRH by 45% and IGF-1 by 20%...It is important to note that the vast majority of GHRH-secreting tumours (lung, pancreas, phaeochromocytoma) are expected to be visible on cross-sectional imaging (median diameter 55 mm) (1). Therefore, we suggest that a chest X-ray and an abdominal ultrasound checking the adrenal glands and the pancreas should be included in the routine work-up of newly diagnosed acromegaly patients.
  • ||||||||||  Clinical, Journal:  Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients. (Pubmed Central) -  Jun 22, 2021   
    ML-based models could aid neurosurgeons in the preoperative prediction of TTS response for patients with acromegaly, and could contribute to determining individual treatment strategies. We demonstrate gender-specific characteristics and an evolving spectrum of clinical presentation with implications for earlier diagnosis and personalized management of acromegaly.
  • ||||||||||  Journal:  Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. (Pubmed Central) -  Jun 22, 2021   
    Our study suggests that a lower number of CD8+ lymphocytes is associated with cavernous sinus invasion and resistance to treatment with first-generation somatostatin analogues in acromegaly patients. These results highlight a potential role of the tumour immune microenvironment in determining the prognosis of somatotroph pituitary tumours.
  • ||||||||||  Clinical, Review, Journal:  Acromegaly in the elderly patients. (Pubmed Central) -  Jun 22, 2021   
    Available data on acromegaly in the elderly patient are sparse, but point to important differences. Further studies are needed comparing elderly with younger patients with acromegaly to better define a tailored diagnostic and therapeutic management.
  • ||||||||||  Journal:  Increased ATP-synthesis might counteract hepatic lipid accumulation in acromegaly. (Pubmed Central) -  Jun 22, 2021   
    This is accompanied by a decreased ratio of unsaturated-to-saturated lipids in hepatocytes and by a metabolomic profile reflecting the increase in mitochondrial activity. Thus, these findings help to better understand GH-regulated antisteatotic pathways and provide a better insight into potential novel therapeutic targets for treating NAFLD.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide long acting release) / Novartis
    Clinical, Journal, HEOR:  Soluble Klotho: a possible predictor of quality of life in acromegaly patients. (Pubmed Central) -  Jun 22, 2021   
    Patients experienced improved QoL during PAS-LAR, either as monotherapy or in combination with PEGV. Soluble Klotho concentrations appear to be a useful marker of QoL in acromegaly patients but the underlying mechanisms remain to be investigated.